Soft Plaque and CAC Zero: When a Calcium Score of Zero Isn't a Free Pass

Vulnerable plaque rupture with thrombus formation in coronary artery

The coronary calcium score has a real blind spot: non-calcified plaque. By design, the CAC scan only detects calcified material above 130 Hounsfield Units. Mature, stable atherosclerotic plaques are calcified and show up. But early atherosclerotic lesions, the lipid-rich "vulnerable" plaques most prone to rupture, and the soft components within mixed plaques are invisible on a non-contrast CAC scan. For most middle-aged and older adults this blind spot is small — calcified plaque correlates well enough with total plaque burden to make CAC clinically useful. But there are specific populations where the blind spot matters and a calcium score of zero can mislead.

What CAC Misses
Vulnerable Plaque
"CAC-Zero MI"
High-Risk Patients with CAC = 0
CCTA as a Complement to CAC
Young Adults and Soft Plaque
Elevated Lp(a) and Soft Plaque
Familial Hypercholesterolemia
Practical Approach
Research Papers and References
Connections
Featured Videos

What CAC Misses

Atherosclerosis progresses through stages, and CAC is sensitive to the late stages but not the early ones:

Endothelial dysfunction — the earliest stage; not visible on any imaging modality
Lipid accumulation in the artery wall — foam cells, fatty streaks; invisible on CAC
Soft plaque formation — lipid-rich core with thin fibrous cap; invisible on CAC, visible on CCTA
Mixed plaque — partial calcification of soft plaque; partly visible on CAC
Mature calcified plaque — stable, dense calcification; clearly visible on CAC

CAC catches stages 4 and 5 reliably. Stages 1–3 are the soft-plaque blind spot. The good news: stages 4 and 5 are when most clinical events occur in the population, which is why CAC is such a powerful risk-stratification tool. The bad news: stages 1–3 are when the lipid-rich, vulnerable plaque most prone to acute rupture exists in greatest concentration.

Vulnerable Plaque

The acute coronary syndromes — STEMI, NSTEMI, unstable angina — are caused predominantly by plaque rupture, not by progressive narrowing. The plaque most likely to rupture has these features:

Large lipid-rich core
Thin fibrous cap (<65 µm)
Macrophage-rich infiltrate
Sparse smooth muscle cells
Minimal calcification — calcification is a stabilization process

This is why high-density calcified plaque on a follow-up CAC after years of statin therapy is reassuring, while soft plaque on CCTA is worrying: density tracks stability. The Agatston score's density factor weights stable plaque higher, by design.

"CAC-Zero MI"

The "CAC-zero MI" is the rare but real phenomenon of a patient suffering an acute coronary event with a normal calcium score. Studies suggest 1–3% of MIs occur in patients with CAC = 0. Common patterns:

Younger patients (under 50) — not enough time for calcification, but soft plaque present
Heavy smokers — pro-thrombotic and pro-rupture independent of plaque burden
Cocaine users — vasospasm and pro-thrombotic
Spontaneous coronary artery dissection (SCAD) — particularly in women, peripartum
Coronary spasm — vasospastic angina (Prinzmetal)
Microvascular disease — especially in diabetic patients
Familial hypercholesterolemia — soft plaque develops early
Markedly elevated Lp(a) — pro-thrombotic, pro-inflammatory effects independent of total plaque burden
Connective tissue or autoimmune disease — SLE, RA accelerate plaque rupture

The clinical history matters more than the test result in identifying these patients. Symptoms always override imaging.

High-Risk Patients with CAC = 0

Specific scenarios where a CAC = 0 result should not provide complete reassurance:

Symptomatic patient with chest pain — CAC = 0 does not exclude soft-plaque-mediated ischemia or non-atherosclerotic causes; further workup (CCTA or stress test) needed
Family history of premature CAD with FH or markedly elevated Lp(a) — consider CCTA
Active smoker, especially with other risk factors — CAC = 0 does not negate smoking-driven event risk
Connective tissue disease, especially SLE — consider CCTA in younger patients
Newly diagnosed type 2 diabetes — CAC = 0 reassuring but follow-up sooner than usual

CCTA as a Complement to CAC

CT coronary angiography (CCTA) addresses the soft-plaque blind spot directly. With IV iodinated contrast and gated cardiac CT, CCTA visualizes both calcified and non-calcified plaque, vessel lumen geometry, and (with FFR-CT) the functional impact of stenoses.

When CCTA adds meaningful information beyond CAC:

Symptomatic patients regardless of CAC result
Asymptomatic patients with strong family history of premature CAD and CAC = 0 (rule out soft plaque)
Asymptomatic patients with markedly elevated Lp(a) or FH with CAC = 0
Following up an unexpectedly low CAC score that conflicts with clinical risk picture
One-time anatomic snapshot in patients with rapid risk-factor evolution (new diabetes, sustained dyslipidemia)

Trade-offs: higher cost ($500–$2,000 vs $99–$200), higher radiation (3–10 mSv vs 1 mSv), need for IV contrast and beta-blockade, and longer scan time. CCTA is generally not appropriate as a first-line screening test in low-to-intermediate risk asymptomatic adults — CAC remains the right starting point in that population.

Young Adults and Soft Plaque

In adults under 40, atherosclerosis is often soft plaque only — calcification has not had time to develop. A CAC = 0 in a 30-year-old with strong family history may be falsely reassuring. The case for additional evaluation in young adults:

Family history of premature CAD (male first-degree relative < 55, female < 65)
Markedly elevated Lp(a) (> 100 nmol/L or > 50 mg/dL)
Familial hypercholesterolemia (LDL-C > 190 mg/dL or genetically confirmed)
Symptoms suggestive of cardiac etiology

For these patients, a complete picture often requires lipid markers (ApoB, Lp(a)), genetic testing where appropriate, and consideration of CCTA. CAC alone is not sufficient.

Elevated Lp(a) and Soft Plaque

Lipoprotein(a) is a genetically determined LDL-like particle linked to apolipoprotein(a). Elevated Lp(a) is associated with:

Increased pro-thrombotic activity (apolipoprotein(a) shares structural homology with plasminogen)
Inflammatory and oxidative effects on the arterial wall
Accelerated atherosclerosis even at "normal" LDL-C
Calcific aortic valve stenosis in older age
An event-rate increase even at low CAC scores

Patients with markedly elevated Lp(a) (above 100 nmol/L or 50 mg/dL) may have normal or low CAC scores yet substantial soft-plaque burden. CCTA may be warranted, and lipid management should be aggressive (LDL-C targets below standard population goals).

Familial Hypercholesterolemia

Familial hypercholesterolemia is a genetic disorder (typically LDLR, APOB, or PCSK9 mutations) causing severely elevated LDL-C from birth. FH patients develop atherosclerosis decades earlier than the general population, often with substantial soft-plaque burden by their 30s. CAC scoring in FH:

Detects calcified plaque progression earlier than non-FH controls
Underestimates total burden because soft plaque dominates in younger FH patients
Should be combined with CCTA evaluation in young or symptomatic FH patients
Should not be used to defer therapy — FH patients need lifelong intensive lipid-lowering regardless of imaging

Practical Approach

For the typical asymptomatic middle-aged adult:

Lipid panel, ApoB, Lp(a) once
ASCVD risk calculation
CAC if intermediate risk or family history
Manage based on integrated picture

For the high-risk asymptomatic patient (FH, markedly elevated Lp(a), strong premature CAD family history):

Lipid panel, ApoB, Lp(a) once
Comprehensive risk assessment
CAC scoring
If CAC > 0, manage as appropriate
If CAC = 0 but high baseline genetic/lipid risk: consider CCTA to rule out soft plaque
Manage aggressively regardless of imaging if FH or high Lp(a)

For the symptomatic patient at any age: CAC alone is not the right test — CCTA, stress test, or invasive evaluation as clinically indicated. See the CAC vs Other Tests page.

Back to Table of Contents